Turn Therapeutics Inc. (TTRX)
Health Care · Topical immunomodulators for inflammatory skin disease · Nasdaq
Turn Therapeutics is developing a non-systemic topical immunomodulator (GX-03) containing polyhexanide for moderate-to-severe eczema and onychomycosis, with topline results expected mid-2026.
What Turn Therapeutics Inc. does
Turn Therapeutics is a clinical-stage dermatology company developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases. The company's lead program, GX-03, is a topical formulation containing polyhexanide (PHMB) being evaluated in a randomized, double-blind clinical trial for moderate-to-severe eczema, with topline results expected mid-2026. GX-03 is also being advanced for onychomycosis (fungal nail infections) based on preclinical data demonstrating nail penetration and antifungal activity. The company leverages a lean operational model with contractors and vendors while pursuing FDA drug approvals for two skin conditions that currently require pharmaceutical approval for marketing.
Themes: ["Topical immunomodulators / dermatology"]
Fundamentals
- Price$9.44 as of 2026-07-10 close
- Market cap$281M as of 2026-07-13
- 1-year return+139.6% as of 2026-07-10 close
- ROE-117.3% as of 2026-07-13
- Debt / equity0.97 as of 2026-07-13
- Beta-0.23 as of 2026-07-13
Key risks (from latest filing)
["Clinical development risk: topline results from the Phase 2 eczema trial are expected mid-2026; failure to demonstrate efficacy or safety could halt the lead program."]
Competitors & peers
- Dupilumab (Sanofi/Regeneron) – monoclonal antibody for atopic dermatitis
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.